胡桃醌-PLGA纳米粒制备及对A375恶黑细胞的体外抗肿瘤作用

岳武恒; 梅瑞; 蔡娟; 钱汉清; 刘宝瑞; 邹征云

doi:10.13422/j.cnki.syfjx.20190114

您当前的位置：

首页 >

文章列表页 >

胡桃醌-PLGA纳米粒制备及对A375恶黑细胞的体外抗肿瘤作用

药理 | 更新时间：2021-02-09

- 胡桃醌-PLGA纳米粒制备及对A375恶黑细胞的体外抗肿瘤作用
- Preparation of Juglone-loaded PLGA Nanoparticles and Its Anti-tumor Effect on Melanoma A375 Cells in Vitro
- 中国实验方剂学杂志 2019年25卷第4期页码：87-93
- 作者机构：
  
  1.南京中医药大学　中西医结合鼓楼临床医学院，南京　 210008；
  2.南京大学　医学院　附属鼓楼医院，南京　 210008
- 作者简介：
  
  岳武恒，在读硕士，从事恶性肿瘤的中西医结合及生物免疫治疗研究，E-mail: 737281405@qq.com
  *邹征云，博士，主任医师，硕士生导师，从事恶性肿瘤生物免疫治疗的研究，Tel：025-83106666, E-mail：zouzhengyun001@163.com
- 基金信息：
  
  国家重点研发计划专项(2017YFC1308900);南京市医学科技发展项目(ZKX15012);中央高校基本科研项目(021414380427)
- DOI：10.13422/j.cnki.syfjx.20190114
  中图分类号： R22;R242;R2-031;R285.5;R273
- 纸质出版日期：2019-02-20，
  
  网络出版日期：2018-10-19，
  
  收稿日期：2018-07-19，
- 稿件说明：
扫描看全文
岳武恒, 梅瑞, 蔡娟, 等. 胡桃醌-PLGA纳米粒制备及对A375恶黑细胞的体外抗肿瘤作用[J]. 中国实验方剂学杂志, 2019,25(4):87-93.

Wu-heng YUE, Rui MEI, Juan CAI, et al. Preparation of Juglone-loaded PLGA Nanoparticles and Its Anti-tumor Effect on Melanoma A375 Cells in Vitro[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2019,25(4):87-93.
岳武恒, 梅瑞, 蔡娟, 等. 胡桃醌-PLGA纳米粒制备及对A375恶黑细胞的体外抗肿瘤作用[J]. 中国实验方剂学杂志, 2019,25(4):87-93. DOI： 10.13422/j.cnki.syfjx.20190114.

Wu-heng YUE, Rui MEI, Juan CAI, et al. Preparation of Juglone-loaded PLGA Nanoparticles and Its Anti-tumor Effect on Melanoma A375 Cells in Vitro[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2019,25(4):87-93. DOI： 10.13422/j.cnki.syfjx.20190114.

摘要

目的：

制备胡桃醌(juglone，Jug)聚乳酸-羟基乙酸(poly lactic-co-glycolic acid，PLGA)纳米粒(Jug-PLGA-NPs)，并考察其理化性质、体外释放特征及对A375细胞的体外影响。

方法：

采用乳化挥发法制备Jug-PLGA-NPs，对其粒径、包封率、载药率以及体外释放特征进行考察；荧光显微镜观察PLGA-NPs在体外细胞的摄取情况，小动物活体成像仪观测PLGA-NPs在BALB/c荷瘤裸鼠尾静脉注射后体内的分布；用噻唑蓝(thiazolyl blue tetrazolium bromide，MTT)比色法检测其对A375细胞增殖抑制作用，流式细胞仪进行细胞凋亡率及细胞周期检测；蛋白免疫印迹法检测蛋白激酶B(protein kinase B，Akt)，磷酸化-Akt(p-Akt)，周期蛋白D

(cyclinD

)的表达情况。

结果：

制备的Jug-PLGA-NPs平均粒径为(149.6±21.5)nm，包封率为(68.39±2.51)%，载药率(5.07±0.98)%，具有良好的缓释特征。PLGA-NPs在体外细胞摄取和体内活体成像中具有良好的穿透和靶向性能。不同浓度Jug-PLGA-NPs均能明显抑制A375细胞增殖、促进细胞凋亡，呈明显时间浓度依赖性(

0.05)，且48 h作用略优于等浓度Jug；其机制可能与调节Akt磷酸化水平，下调cyclinD

表达(

0.05)，阻滞细胞于G

期有关(

0.05)。

结论：

负载Jug的PLGA纳米微粒制备简便，具有良好的药物缓释、肿瘤靶向及抗肿瘤能力，为未来Jug的临床应用提供了一种新的药物剂型。

Abstract

Objective:

To prepare Juglone-loaded poly lactic-co-glycolic acid nanoparticles (Jug-PLGA-NPs)

and investigate their physicochemical properties

release characteristics

in vitro

and anti-tumor activities on A375 melanoma cells

in vitro

Method:

Jug-PLGA-NPs were prepared by emulsification-solvent evaporation method. Then the particle size

encapsulation efficiency

drug loading rate and

in vitro

release characteristics were investigated. Fluorescence microscopy was used to observe the uptake of PLGA-NPs

in vitro

. The distribution of PLGA-NPs in BALB/c nude mice after tail vein injection was observed by the small living animal imaging system. Their inhibition effect on proliferation of A375 cells was detected by thiazolyl blue tetrazolium bromide (MTT) assay. Apoptosis rate and cell cycle detection were performed by flow cytometry. Western blot was used to determine the protein kinase B (Akt)

phosphorylated Akt (p-Akt) and cyclinD

Result:

The average particle size of the prepared Jug-PLGA-NPs was (149.6±21.5) nm

entrapment rate of (68.39±2.51)%

and drug-loading rate of (5.07±0.98)%

showing good sustained-release characteristics. PLGA-NPs showed good penetration and targeting properties in cellular uptake

in vitro

and

in vivo

imaging. Different concentrations of Jug-PLGA-NPs could significantly inhibit the proliferation and promote apoptosis of A375 cells in a time and concentration dependent manner (

0.05)

and its 48 h effect was superior to that of the same concentration of Jug. The mechanism may be related to the regulation of Akt phosphorylation level

down-regulation of cyclinD

expression (

0.05) and the cell-cycle arrest in G

phase (

0.05).

Conclusion:

The Jug-PLGA-NPs are easy to prepare and have good sustained-release characteristics

tumor targeting and anti-tumor ability

providing a new pharmaceutical dosage form for the future clinical application of Jug.

关键词

胡桃醌聚乳酸-羟基乙酸纳米微粒黑色素瘤A375细胞

Keywords

juglonepoly lactic-co-glycolic acid (PLGA)nanoparticlesmelanomaA375 cells

references

Siegel R L, Miller K D, Ahmedin-Jemal D P. Cancer statistics, 2018[J].CA Cancer J Clin,2018,68(1):7-30.

BAO L, Kimzey A, Sauter G, et al. Prevalent overexpression of prolyl isomerase Pin1 in human cancers[J].Am J Pathol,2004,164(5):1727-1737.

MIN S H, ZHOU X Z, LU K P. The role of Pin1 in the development and treatment of cancer[J].Arch Pharm Res, 2016,39(12):1609-1620.

沈广志，邹桂华，梁婷，等. 核桃楸的化学成分研究进展[J].中国实验方剂学杂志，2015, 21(17):219-224.

Hennig L, Christner C, Kipping M, et al. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone[J].Biochemistry,1998,37(17):5953-5960.

FANG F, QIN Y X, QI L, et al. Juglone exerts antitumor effect in ovarian cancer cells[J].Iran J Basic Med Sci,2015,18(6):544-548.

JI Y B, XIN G S, QU Z Y, et al. Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway[J].Genet Mol Res,2016,15(3):123-131.

Aithal B K, Kumar M R, RAO B N, et al. Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells[J].Cell Biol Int,2009,33(10):1039-1049.

陈丽，张建，汪思应，等. 胡桃醌对小鼠黑色素瘤细胞B16F10体内迁移的影响[J].中国临床药理学与治疗学，2012,17(9):978-982.

Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect[J].Adv Drug Deliv Rev,2011, 63(3):131-135.

杨倩，罗国伟，彭海龙，等. 胡桃醌脂质体的制备及理化性质[J].南昌大学学报：工科版，2015, 37(3):234-239.

黄可心，王晓扬，沈韵桐，等. 胡桃醌叶酸修饰自微乳的体内外靶向性研究[J].中国医院药学杂志，2016,36(4):285-289.

JIN J, ZHANG Y, LI Y, et al. RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells[J].Neoplasma,2012,60(1):92-100.

Arasoglu T, Derman S, Mansuroglu B, et al. Synthesis, characterization and antibacterial activity of juglone encapsulated PLGA nanoparticles[J].J Appl Microbiol,2017,123(6):1407-1419.

ZHANG Z, QIAN H, YANG M, et al. Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment[J].Int J Nanomedicine,2017,12:1593-1605.

GUO J, SI L, KONG Y, et al. Phase Ⅱ， open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification[J].J Clin Oncol,2011,29(21):2904-2909.

Kruiswijk F, Hasenfuss S C, Sivapatham R, et al. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling[J].Oncogene,2016,35(17):2166-2177.

Kim G, Kim J Y, Lim S C, et al.SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development[J].Faseb J,2018,doi:fj201700645doi:fj201700645.

XU G G, Etzkorn F A. Pin1 as an anticancer drug target[J].Drug News Perspect,2009,22(7):399-407.

Hariharan N, Sussman M A. Pin1: a molecular orchestrator in the heart[J].Trends Cardiovasc Med,2014,24(6):256-262.

Bartek J, Lukas J. DNA repair: Cyclin D1 multitasks[J].Nature,2011,474(7350):171-172.

Liou Y C, Ryo A, HUANG H K, et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes[J].Proc Natl Acad Sci U S A,2002,99(3):1335-1340.

TAO X, ZHANG H, Park S S, et al. Loss of Pin1, suppresses hedgehog-driven medulloblastoma tumori-genesis 1[J].Neoplasia,2017,19(3):216-225.

陈静岚，张国屏，孙玉波. 复方青龙衣配合化疗治疗急性白血病23例[J].黑龙江中医药，1996,25(4):26-27.

任生，孟丽，王桂花，等. 中药青龙衣注射剂复合化疗药物介入治疗肺癌13例报告[J].中国中医基础医学杂志，2000, 6(7):27-29.

刘薇，林文翰，季宇彬. 青龙衣毒性作用及体外抗肿瘤作用的实验研究[J].中国中药杂志，2004,29(9):4-10.

CHAO S H, Greenleaf A L, Price D H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription[J].Nucleic Acids Res,2001,29(3):767-773.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于网络药理学和实验验证探讨新疆紫草治疗黑色素瘤的分子机制

胡桃楸叶和果实中胡桃醌含量的动态变化分析

蟾蜍毒素微乳的制备及体外透皮吸收考察

染料木素对A375细胞黑素合成及相关细胞信号通路调控作用的初步探讨